The mean age of presentation is 30 years and studies suggest that screening for SDHAF2 is important in patients with head-and-neck paragangliomas with either a family history of head-and-neck paraganglioma, young age of onset or multiple tumours in whom SDHB, SDHC, and SDHD gene testing was negative (36). Here, SDHC is linked to head and neck paraganglioma.